MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

Search

Ascendis Pharma A-S ADR

Fermé

SecteurSoins de santé

199.81 -2.66

Résumé

Variation du prix de l'action

24h

Actuel

Min

196.73

Max

202.4

Chiffres clés

By Trading Economics

Revenu

56M

-39M

Ventes

57M

158M

Marge bénéficiaire

-24.585

Employés

1,017

EBITDA

51M

2.3M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+21.75% upside

Dividendes

By Dow Jones

Prochains Résultats

13 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.5B

13B

Ouverture précédente

202.47

Clôture précédente

199.81

Sentiment de l'Actualité

By Acuity

50%

50%

153 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 oct. 2025, 23:55 UTC

Actions en Tendance

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 oct. 2025, 23:49 UTC

Résultats

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 oct. 2025, 21:40 UTC

Résultats

Waste Connections 3Q Revenue Rises

21 oct. 2025, 21:14 UTC

Résultats
Principaux Mouvements du Marché

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 oct. 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 oct. 2025, 20:57 UTC

Acquisitions, Fusions, Rachats

DraftKings to Launch Prediction Markets Platform

21 oct. 2025, 20:38 UTC

Résultats

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 oct. 2025, 20:35 UTC

Résultats

Capital One 3Q Sales, Profit Jump

21 oct. 2025, 20:32 UTC

Résultats

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 oct. 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 oct. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 oct. 2025, 23:39 UTC

Market Talk

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 oct. 2025, 23:36 UTC

Market Talk

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 oct. 2025, 22:55 UTC

Acquisitions, Fusions, Rachats

Scentre Says This Forms Part of Capital Management Strategy

21 oct. 2025, 22:55 UTC

Acquisitions, Fusions, Rachats

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 oct. 2025, 22:54 UTC

Acquisitions, Fusions, Rachats

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 oct. 2025, 21:09 UTC

Market Talk
Résultats

Netflix Creators Have Started Using AI in Production -- Market Talk

21 oct. 2025, 20:58 UTC

Market Talk
Résultats

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 oct. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

21 oct. 2025, 20:43 UTC

Résultats

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 oct. 2025, 20:41 UTC

Résultats

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 oct. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 oct. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 oct. 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 oct. 2025, 20:29 UTC

Résultats

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Comparaison

Variation de prix

Ascendis Pharma A-S ADR prévision

Objectif de Prix

By TipRanks

21.75% hausse

Prévisions sur 12 Mois

Moyen 256.29 USD  21.75%

Haut 307 USD

Bas 220 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

17 ratings

17

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

157.66 / 167.29Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

153 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat